Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$1.82 USD
-0.05 (-2.67%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.82 0.00 (0.00%) 7:00 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.82 USD
-0.05 (-2.67%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.82 0.00 (0.00%) 7:00 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Zacks News
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
by Zacks Equity Research
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
by Zacks Equity Research
Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
by Zacks Equity Research
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CareCloud, Inc. (CCLD) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
by Zacks Equity Research
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
by Zacks Equity Research
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
by Zacks Equity Research
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 75% and 6.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -0.65% and 74.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -10% and 39.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
by Zacks Equity Research
United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics are part of the Zacks Industry Outlook article.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -13.24% and 100.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -4.56% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.